Clovis Oncology (CLVS) Prices 11.09M Share Common Offering at $8.05/Sh

Clovis Oncology, Inc. (NASDAQ: CLVS) announced today the pricing of 11,090,000 shares of its common stock in an underwritten public offering at a price to the public of $8.05 per share, before underwriting discounts and commissions. Clovis Oncology also granted to the underwriters a 30-day option to purchase up to an additional 1,663,500 shares of its common stock on the same terms and conditions.

The offering is expected to close on May 21, 2020, subject to customary closing conditions. J. P. Morgan Securities LLC and BofA Securities are acting as joint book-running managers for this offering.

Clovis Oncology intends to use the net proceeds of this offering for general corporate purposes, including repayment, repurchase or refinance of its debt obligations, sales and marketing expenses associated with Rubraca® (rucaparib), funding of its development programs, payment of milestones pursuant to its license agreements, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital.

You May Also Be Interested In

• HomeTrust Bank launches healthcare banking division in Southeast
• EnWave sells second 120kW machine to Procescir, names new CFO
• Realbotix to pilot humanoid robots in UK care homes for elderly